Needham Reiterates Hold Rating on ResMed (RMD)

October 30, 2026 6:13 AM EDT Send to a Friend
Needham analyst Mike Matson reiterated a Hold rating on ResMed (NYSE: RMD).The analyst comments "RMD's F1Q27 revenue and EPS beat ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login